Acetaminophen And Codeine Phosphate Tablet
NDC Package 13107-059-01
Package Information
Acetaminophen And Codeine Phosphate tablets are indicated for the management of mild to moderate pain,where treatment with an opioid is appropriate and for which alternative treatments are inadequate.Limitations of UseBecause of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]Have not provided adequate analgesia, or are not expected to provide adequate analgesiaHave not been tolerated, or are not expected to be tolerated. This formulation utilizes a tablet delivery system. Marketed by Aurolife Pharma, Llc, this product is identified by NDC 13107-059 and is authorized under FDA application ANDA202800.
Identification & Billing
- RxCUI: 993770 - codeine phosphate 15 MG / acetaminophen 300 MG Oral Tablet
- RxCUI: 993770 - acetaminophen 300 MG / codeine phosphate 15 MG Oral Tablet
- RxCUI: 993770 - APAP 300 MG / codeine phosphate 15 MG Oral Tablet
- RxCUI: 993781 - codeine phosphate 30 MG / acetaminophen 300 MG Oral Tablet
- RxCUI: 993781 - acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 13107 - Aurolife Pharma, Llc
- 13107-059 - Acetaminophen And Codeine Phosphate
- 13107-059-01 - 100 TABLET in 1 BOTTLE
- 13107-059 - Acetaminophen And Codeine Phosphate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (13107-059). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 13107-059-01 identifies a specific commercial package of 100 tablet in 1 bottle of Acetaminophen And Codeine Phosphate, a human prescription drug labeled by Aurolife Pharma, Llc. This tablet is formulated for oral use and contains acetaminophen; codeine phosphate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Aurolife Pharma, Llc on April 15, 2013. The current certification is valid through December 31, 2026.
How is this Aurolife Pharma, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 13107005901. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.